Skip to content
HomeLatest newsInnovationAward criteria
speaker

Award criteria

Share Article
share to

About the award:

The Scholars Award is a three-year award in the gross amount of $150,000, which will be paid to the University (the “Recipient”) for the benefit of the Johnson & Johnson Scholar and her research, with the understanding that the Recipient will administer the funds. The Scholars Award will be paid in three (3) installments of U.S. $50,000 per year of the three-year scholarship period, payable in 2022, subject to compliance with the terms and conditions of the program’s Agreement. Winners achievements will also be showcased at a symposium.

The following award criteria applies:

Standards for evaluation:

Judges will use the following criteria to evaluate the applications:

  • Scientific/technical expertise exhibited
  • Novelty/innovation of the research
  • Potential impact of the research
  • Feasibility of the research

You must be a woman working in the field(s) of Science, Technology, Engineering, Mathematics, Manufacturing and Design (STEM2D).

You must be an early to mid-career women working within a STEM2D university department at the time of application at an accredited academic university, institution or design school. Examples include a non-tenured assistant professor, assistant professor or associate professor.

The female scholar should have a minimum degree for the appropriate field:

  • Science; M.D., Ph.D.
  • Technology; Ph.D.
  • Engineering; Ph.D.
  • Math; M.S., Ph.D.
  • Manufacturing; Ph.D.
  • Design; M.A., M.S., MDes, MArch, MFA, MLA, Ph.D.

WiSTEM2D Scholars Award

The Johnson & Johnson WiSTEM²D Scholars Award Program will help develop female leaders and support innovation in STEM fields.

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.